Patient's whole genome reveals risk of diseases and adverse drug responses

Scientists at Stanford and Harvard Universities collaborated to assess the clinical usefulness of analyzing a patient's full genome for disease risks and unusual drug responses. The work brings closer to reality the concept that whole-genome sequencing might one day play a clinical role.

Read the whole article on Physorg

More from Physorg